title: Targeted gold nanoparticles enhance sensitization of prostate tumors to megavoltage radiation therapy in vivo.
abstract: We report potent radiosensitization of prostate cancers in vitro and in vivo using goserelin-conjugated gold nanorods. Progressive receptor-mediated internalization of conjugated nanorods over time increases the radiation interaction cross-section of cells and contributes to the effects observed in vitro. The low concentrations of gold required, the long interval between injection of nanoparticles and radiation, and the use of megavoltage radiation to generate radiosensitization in vivo foretell the possibility of eventual clinical translation of this approach.
  
  
  BACKGROUND
  The ability of gold nanoparticles (AuNPs) to enhance the effect of physical radiation dose on tumor cells is known. This radiosensitization effect is thought to result from an increased number of photoelectric absorption events and the increased number of electrons present in gold. The authors here sought to further increase the amount and specificity of gold accumulation in prostatic cancer cells by conjugating gold nanorods to goserelin, a synthetic luteinizing hormone releasing hormone (LHRH) analogue that would bind to the LHRH receptor overexpressed in prostate cancers. It was shown that tumour cells were more sensitive to megavoltage radiation therapy. It is hoped that there would be eventual clinical translation of this approach.
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Tatiana
authors: T
authors: Wolfe
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Dev
authors: D
authors: Chatterjee
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA; SoonChunHyang University Hospital, Seoul, South Korea.
authors: Jihyoun
authors: J
authors: Lee
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Jonathan D
authors: JD
authors: Grant
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Shanta
authors: S
authors: Bhattarai
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
authors: Ramesh
authors: R
authors: Tailor
authors: Nanospectra Biosciences Inc., Houston, TX, USA.
authors: Glenn
authors: G
authors: Goodrich
authors: University of Sao Paulo, Ribeirão Preto, Sao Paulo, Brazil.
authors: Patricia
authors: P
authors: Nicolucci
authors: The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: skrishnan@mdanderson.org.
authors: Sunil
authors: S
authors: Krishnan
mesh_terms: D000818:Animals; D006046:Gold / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017273:Goserelin / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D053768:Metal Nanoparticles / Q000737:chemistry / Q000627:therapeutic use*; D051379:Mice; D043942:Nanotubes / Q000737:chemistry; D011467:Prostate / Q000473:pathology / Q000528:radiation effects*; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011838:Radiation-Sensitizing Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*
chemical_list: D011838:Radiation-Sensitizing Agents; D017273:Goserelin; D006046:Gold
keywords: Conjugated; Gold nanoparticles; Goserelin acetate; Megavoltage radiation therapy; Prostate cancer; Tumor targeted delivery
references: Nanoscale. 2012 Aug 21;4(16):4830-8
references: 22767423
references: Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):270-6
references: 21163591
references: J Clin Oncol. 2010 Mar 1;28(7):1106-11
references: 20124169
references: Phys Med Biol. 2004 Sep 21;49(18):N309-15
references: 15509078
references: PLoS One. 2013;8(4):e62425
references: 23638079
references: Biomaterials. 2010 Sep;31(25):6574-81
references: 20542560
references: Phys Med Biol. 2005 Aug 7;50(15):N163-73
references: 16030374
references: Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):686-92
references: 22795805
references: ACS Nano. 2014 Jan 28;8(1):104-12
references: 24377302
references: Nanomedicine (Lond). 2013 Oct;8(10):1601-9
references: 23265347
references: Int J Radiat Oncol Biol Phys. 2001 Nov 15;51(4):1002-7
references: 11704324
references: J Control Release. 2000 Mar 1;65(1-2):271-84
references: 10699287
references: Eur J Pharm Biopharm. 2011 Apr;77(3):417-23
references: 21093587
references: Nanotechnology. 2009 Sep 16;20(37):375101
references: 19706948
references: Phys Med Biol. 2010 Jun 7;55(11):3045-59
references: 20463371
references: Phys Med Biol. 2011 Aug 7;56(15):4631-47
references: 21734337
references: Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):67-74
references: 17765406
references: J Clin Endocrinol Metab. 2009 May;94(5):1761-7
references: 19190109
references: Eur J Pharm Biopharm. 2011 Apr;77(3):407-16
references: 21195759
references: Nanotechnology. 2011 Jul 15;22(28):285101
references: 21654036
references: Radiat Oncol. 2007 Aug 26;2:31
references: 17718927
references: Radiat Res. 2010 Jun;173(6):719-28
references: 20518651
references: J Urol. 2000 Feb;163(2):623-9
references: 10647698
references: Phys Med Biol. 2009 Aug 21;54(16):4889-905
references: 19636084
references: Phys Med Biol. 2013 May 21;58(10):3075-87
references: 23594417
references: Appl Phys Lett. 2011 May 9;98(19):193702
references: 21915155
references: Cancer Lett. 2014 May 28;347(1):151-8
references: 24530512
references: J Biomed Nanotechnol. 2014 Jul;10(7):1205-16
references: 24804541
references: Phys Med Biol. 2010 Feb 21;55(4):931-45
references: 20090183
references: Phys Med Biol. 2014 May 7;59(9):2249-63
references: 24733041
references: Biomed Microdevices. 2009 Aug;11(4):925-33
references: 19381816
references: Nanomedicine. 2009 Jun;5(2):136-42
references: 19480049
references: N Engl J Med. 1997 Jul 31;337(5):295-300
references: 9233866
references: Med Phys. 2010 Jul;37(7):3809-16
references: 20831089